[/]: The European Patent Office (EPO) last week made its final determination, vetoed a controversial embryonic stem cell patents. For this verdict, researchers should be gushing, and biotechnology are likely laughed.
This patent covers the United States, University of Wisconsin researchers James Thomson developed technology, namely the training come from preimplantation embryos of primate embryonic stem cells. In last week's ruling, the EPO supported the 2007 summer decision, rejected the patents.
Earlier this year, the United States Patent Office supports the patent, as well as the other two and embryonic stem cells source and copy the relevant patents. These three patents by Wisconsin Alumni Research Foundation (WARF) in 1995, due to New York City public patent Foundation and the Los Angeles municipal taxpayer and consumer rights (FTCR) Joint complaints, in October 2006 for a retrial. The Foundation claims that these patents impede stem cell research, and in Thomson before other researchers have developed this technology.
In a decision of the EPO with regard to the current statement, the expansion of the Appeals Committee said that, in accordance with the European Patent Convention, "could not be pleaded guilty to one count of including the use of human embryos and the destruction of the patent of invention."
United Kingdom National Institute of stem cell biology and developmental genetics Director Robin Lovell-Badge said: "I can imagine many people breathed a sigh of relief. There will be many other biotech companies on stem cells application or derivative products, or apply it to the filter method. ”
However, there are also people who believe that this decision for those who devote themselves to the development of embryonic stem cell technology in biotechnology companies is a blow. It is reported that the EPO rulings can be applied to approximately 200 other European patent applications pending.
However, the EPO decision declares that this decision does not apply to the usual human stem cell patents. David Earp is stem cell biotechnology company Geron's Chief Patent Counsel, the company in Europe has a number of pending patent applications. He said that he believed that this decision applies only to the patent, the Patent Office soon WARF will deal with the remaining Geron.
No comments:
Post a Comment